BaxDuo - Arctic
The BaxDuo-Arctic study is looking for people with CKD & high blood pressure to join this clinical trial.
BaxDuo-Arctic is investigating whether baxdrostat with dapagliflozin (also called Forxiga™ or Farxiga™) may work better than dapagliflozin on its own in people with CKD and high blood pressure. Because baxdrostat and dapagliflozin work in slightly different ways, it is thought they may be able to work together to lower your blood pressure and protect your kidneys from further damage.
You may be eligible to participate in this study if you:
- Are at least 18 years of age
- Have CKD and high blood pressure
- Have not received any dialysis treatment for at least 3 months
Additional criteria will be assessed to determine eligibility.
- dapagliflozin + baxdrostat OR
- dapagliflozin + placebo (placebo contains no active medicine)
About the study
The study duration is between 27 – 28 months in which you will be asked to come to 13-15 clinic appointments and take 2 tablets once a day for the duration of the study.
While you are in the study, you will be asked to have some tests and assessments to make sure the study is right for you, to monitor your health and to see if the study treatments are working.
These assessments include:
- Questions about your health and medicines you take
- Physical exams and vital signs
- Blood and urine tests
- Heart tests (electrocardiograms, also called ECGs)
